ABSTRACT
Deep brain stimulation (DBS) has garnered widespread use as an effective treatment for advanced Parkinson’s Disease (PD). Conventional DBS (cDBS) provides electrical stimulation to the basal ganglia at fixed amplitude and frequency, yet patients’ therapeutic needs are often dynamic with residual symptom fluctuations or side-effects. Adaptive DBS (aDBS) is an emerging technology that modulates stimulation with respect to real-time clinical, physiological, or behavioral states, enabling therapy to dynamically align with patient-specific symptoms. Here, we report a novel aDBS algorithm intended to mitigate movement slowness by delivering targeted stimulation increases during movement using decoded motor signals from the brain. Compared to cDBS and a control algorithm that decreases stimulation during movement, our approach demonstrates enhanced clinical efficacy, with improvements in movement speed, reduced dyskinesia, and better patient-reported therapeutic quality. Furthermore, we demonstrate proof-of-principle of a machine learning pipeline capable of remotely optimizing aDBS parameters in a home setting. This work illustrates the potential of movement-responsive aDBS as a new therapeutic approach and highlights how machine learning assisted programming can simplify optimization to facilitate translational scalability.
Competing Interest Statement
T.C.D. is a current employee of iota Biosciences, Inc., but was not an employee when the study was designed and initiated. S.J.L. is a consultant for iota Biosciences, Inc. P.A.S received fellowship program financial support from Medtronic, Inc. All other authors declare no competing interests. No commercial entity played any role in experimental design or analysis/interpretation of study results, provided financial support for this study, or has any obvious means of gaining or losing financially through this publication. A provisional patent application has been submitted for the movement-responsive aDBS and optimization approach (applicant: UCSF; application number: 65/531,506; inventors: T.C.D, S.J.L., D.L., J.A.H., P.A.S.).
Clinical Trial
NCT03582891
Funding Statement
The study was funded by a Weill Investigators Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of California, San Francisco gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Anonymized data are available on the Dryad repository at https://doi.org/10.5061/dryad.4xgxd25hw.
